The Power of 24-hour: Co-designing Intervention Components
- Disease/Condition
- Overweight and Obesity
- Drug/Device/Intervention
- Concept mapping: brainstorm
- Study type
- Observational
- Intervention type
- other
- Primary sponsor
- University Hospital, Ghent
- Location
- Ghent, Belgium
- Phase
- N/A
- Start date
- Sep 05, 2023
- End date
- Mar 31, 2025
- Enrollment
- 210 participants
Themes,Score of effectiveness,Score of feasibility,Score of modifiability
Most of the existing lifestyle interventions in adults with overweight or obesity focus on
 one movement behavior in isolation (i.e. moderate to vigorous physical activity (MVPA)).
 However, recent research suggests to incorporate all movement behaviors performed in one day
 to explore the possible synergistic health effects of targeting more than one behavior.
 Moreover, more optimal 24-hour movement behavior compositions are related with better
 cardiometabolic health. Literature shows that adults with obesity have less optimal 24-hour
 compositions (8-9). Therefore it would be of interest to discover the needs related to an
 optimal 24-hour movement behavior intervention for a group of adults with overweight and
 obesity using co-design to develop an intervention.
 
 This study will conduct a concept mapping protocol to explore the needs to of people with
 overweight and obesity to change their sedentary behavior into more physical activity as well
 to include the opinion of health care providers (HCP are physiotherapists) on the needs of
 their patients.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06269159
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06269159 through Pure Global AI's free database. This phase not specified trial is sponsored by University Hospital, Ghent and is currently Recruiting. The study focuses on Overweight and Obesity. Target enrollment is 210 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.